In Vivo Immune Responses to Tumors Induced by DC-Induced Anti-tumor Immune Responses In Vivo
| Species . | Tumor . | DC Preparation . | Tumor AG . | Vaccination . | Outcome . | Author (reference) . |
|---|---|---|---|---|---|---|
| . | . | . | . | (Pre/post) . | . | . |
| Mouse | MCA-induced sarcoma (McSa-1) | Spleen DC | Sarcoma cells | 18 Days post IV | Some dose-dependent prolonged survival | Knight et al 1985519 |
| 0 Day IV | All died | |||||
| Mouse | Fibrosarcoma (CSAIM) | T-depleted spleen cells | Tumor membranes | 5 Weekly pre SC | Reduced tumor growth | Shimizu et al 1991502 |
| Mouse | MCA-induced fibrosarcoma (S1509a) | Unseparated epithelial cells (%LC) | Tumor lysate | 7 Days pre SC | Reduced tumor growth | Grabbe et al 1991525 |
| Mouse | Lymphoma (BCL1) | Splenic low density (BSA) | IgM idiotype | 10 Days pre IV | 23/28 Treated alive | Flamand et al 1994535 |
| 5 Days Ig IV | 2/20 Untreated alive | |||||
| Mouse | C3 sarcoma HPV-16 | Splenic | HPV-16 E7 peptide | Days pre IV | Tumor protection | Ossevoort 1995536 |
| Mouse | Lewis lung-(3LL) carcinoma | BM generated (GM-CSF/IL-4) | MUT-1 peptide | 0-7 Days post IV or SC | No tumor growth | Mayordomo et al 1995202 |
| C3 sarcoma-HPV16 melanoma-OVAM-05 | HPV16-E7 peptide OVA peptide | 7, 15, 21 Days post | Established tumor regression | |||
| Mouse | MCA-induced fibrosarcoma (MCA-205) mammary adenocarcinoma (TS/A) | BM generated (GM-CSF/IL-4) | Acid-eluted tumor peptides | 4-7 Days post IV (multiple) | Reduced tumor growth | Zitvogel et al 1996426 |
| C3 embryonal fibroblasts-HPV 16 | ||||||
| Mouse | Melanoma (B16-OVA) | BM generated (GM-CSF/IL-4) | OVA peptide | 0, 7 Days pre SC | No tumor growth | Celluzzi et al 1996203 |
| Mouse | LBSN retroviral transformed fibroblast (F1-B gal) mastocytoma (P815-B gal) | BM generated (GM-CSF) transduced DC line D2SC/1 | B gal protein | 10-12 & 5-7 Days pre IP | No tumor growth | Paglia et al 1996537 |
| Mouse | Thymoma (EL-4-OVA) | BM generated (GM-CSF) | OVA peptide | 8 Days pre IV/IP | 5/6 relapse (27 tumor cells) | Porgador et al 1996529 |
| 5/6 free (107 tumor cells) | ||||||
| Mouse | 3T3 Cells-human p53 mutant (D459) | BM generated (GM-CSF/IL-4) | p53 Mutant peptide | 8 Days then every 4-5 days (post) | Reduced tumor growth | Gabrilovich et al 1996427 |
| Mouse | MCA-induced fibrosarcoma (natural p53 mutant) | BM generated (GM-CSF/IL-4 or TNF) | p53 Mutant peptide | 7 & 14 Days pre IV | Reduced tumor growth | Mayordomo et al 1996428 |
| 7 & 14 Days post IV | Tumor regression or inhibition | |||||
| Mouse | MC38 adenocarcinoma | BM generated (GM-CSF)/MC38 fusion cells | MC38 fusion cell | 14 & 28 Days pre SC or IV | No tumor growth | Gong et al 1997526 |
| 4 & 18 Days post IV | 24/25 No metastases at 28 days | |||||
| Rat | Sarcoma (HSNic) | Mesenteric lymphatic DC | In vivo loading via PP | 5 Weeks pre IP vaccination for each | 9/16 Tumor free | Gyure et al 1987263 |
| In vitro loading | 0/5 Tumor free (reduced tumor growth) | |||||
| Human | Non-Hodgkin's lymphoma | Blood DC | Ig idiotype | 0, 1, 2 L 5-6 mo (+14 day protein boost) post SLC | T-lymphocyte response. Possible tumor response | Hsu et al 1996532 |
| Human | Prostate cancer | GM/IL-4 Mo-DC | Prostate-specific membrane antigen | 4-6 Weekly (≤4 IV infusions) | Possible T-lymphocyte response | Murphy et al 1996533 |
| Species . | Tumor . | DC Preparation . | Tumor AG . | Vaccination . | Outcome . | Author (reference) . |
|---|---|---|---|---|---|---|
| . | . | . | . | (Pre/post) . | . | . |
| Mouse | MCA-induced sarcoma (McSa-1) | Spleen DC | Sarcoma cells | 18 Days post IV | Some dose-dependent prolonged survival | Knight et al 1985519 |
| 0 Day IV | All died | |||||
| Mouse | Fibrosarcoma (CSAIM) | T-depleted spleen cells | Tumor membranes | 5 Weekly pre SC | Reduced tumor growth | Shimizu et al 1991502 |
| Mouse | MCA-induced fibrosarcoma (S1509a) | Unseparated epithelial cells (%LC) | Tumor lysate | 7 Days pre SC | Reduced tumor growth | Grabbe et al 1991525 |
| Mouse | Lymphoma (BCL1) | Splenic low density (BSA) | IgM idiotype | 10 Days pre IV | 23/28 Treated alive | Flamand et al 1994535 |
| 5 Days Ig IV | 2/20 Untreated alive | |||||
| Mouse | C3 sarcoma HPV-16 | Splenic | HPV-16 E7 peptide | Days pre IV | Tumor protection | Ossevoort 1995536 |
| Mouse | Lewis lung-(3LL) carcinoma | BM generated (GM-CSF/IL-4) | MUT-1 peptide | 0-7 Days post IV or SC | No tumor growth | Mayordomo et al 1995202 |
| C3 sarcoma-HPV16 melanoma-OVAM-05 | HPV16-E7 peptide OVA peptide | 7, 15, 21 Days post | Established tumor regression | |||
| Mouse | MCA-induced fibrosarcoma (MCA-205) mammary adenocarcinoma (TS/A) | BM generated (GM-CSF/IL-4) | Acid-eluted tumor peptides | 4-7 Days post IV (multiple) | Reduced tumor growth | Zitvogel et al 1996426 |
| C3 embryonal fibroblasts-HPV 16 | ||||||
| Mouse | Melanoma (B16-OVA) | BM generated (GM-CSF/IL-4) | OVA peptide | 0, 7 Days pre SC | No tumor growth | Celluzzi et al 1996203 |
| Mouse | LBSN retroviral transformed fibroblast (F1-B gal) mastocytoma (P815-B gal) | BM generated (GM-CSF) transduced DC line D2SC/1 | B gal protein | 10-12 & 5-7 Days pre IP | No tumor growth | Paglia et al 1996537 |
| Mouse | Thymoma (EL-4-OVA) | BM generated (GM-CSF) | OVA peptide | 8 Days pre IV/IP | 5/6 relapse (27 tumor cells) | Porgador et al 1996529 |
| 5/6 free (107 tumor cells) | ||||||
| Mouse | 3T3 Cells-human p53 mutant (D459) | BM generated (GM-CSF/IL-4) | p53 Mutant peptide | 8 Days then every 4-5 days (post) | Reduced tumor growth | Gabrilovich et al 1996427 |
| Mouse | MCA-induced fibrosarcoma (natural p53 mutant) | BM generated (GM-CSF/IL-4 or TNF) | p53 Mutant peptide | 7 & 14 Days pre IV | Reduced tumor growth | Mayordomo et al 1996428 |
| 7 & 14 Days post IV | Tumor regression or inhibition | |||||
| Mouse | MC38 adenocarcinoma | BM generated (GM-CSF)/MC38 fusion cells | MC38 fusion cell | 14 & 28 Days pre SC or IV | No tumor growth | Gong et al 1997526 |
| 4 & 18 Days post IV | 24/25 No metastases at 28 days | |||||
| Rat | Sarcoma (HSNic) | Mesenteric lymphatic DC | In vivo loading via PP | 5 Weeks pre IP vaccination for each | 9/16 Tumor free | Gyure et al 1987263 |
| In vitro loading | 0/5 Tumor free (reduced tumor growth) | |||||
| Human | Non-Hodgkin's lymphoma | Blood DC | Ig idiotype | 0, 1, 2 L 5-6 mo (+14 day protein boost) post SLC | T-lymphocyte response. Possible tumor response | Hsu et al 1996532 |
| Human | Prostate cancer | GM/IL-4 Mo-DC | Prostate-specific membrane antigen | 4-6 Weekly (≤4 IV infusions) | Possible T-lymphocyte response | Murphy et al 1996533 |